Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 367

1.

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Derosa G, Maffioli P.

Curr Clin Pharmacol. 2012 Aug;7(3):214-28. Review.

PMID:
22432846
2.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
3.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
4.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
5.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
6.
7.

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

Madsbad S.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. doi: 10.1016/j.beem.2009.03.008. Review.

PMID:
19748064
8.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
9.
10.

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Blonde L, Montanya E.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:20-32. doi: 10.1111/j.1463-1326.2012.01575.x. Review.

PMID:
22405266
11.

Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?

Peterson G.

Ann Med. 2012 Jun;44(4):338-49. doi: 10.3109/07853890.2011.653392. Review.

PMID:
22530845
12.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

PMID:
22989472
13.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
14.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
15.

Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.

King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G.

Endocr Pract. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR.

PMID:
23186975
16.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

17.

The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.

Guo XH.

Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11. Review.

PMID:
26439329
18.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
19.
20.

Liraglutide: the therapeutic promise from animal models.

Knudsen LB.

Int J Clin Pract Suppl. 2010 Oct;(167):4-11. doi: 10.1111/j.1742-1241.2010.02499.x. Review.

PMID:
20887299

Supplemental Content

Support Center